¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia (¿Â,¿ÀÇÁ¶óÀÎ)(2ÀÏÂ÷) : 2022-04-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia (¿Â,¿ÀÇÁ¶óÀÎ)(2ÀÏÂ÷) : 2022-04-16
±³À°ÀÏÀÚ : 2022-04-16
±³À°Àå¼Ò : °æÁÖ HICO  
±³À°ÁÖÁ¦ : 2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia (¿Â,¿ÀÇÁ¶óÀÎ)(2ÀÏÂ÷) 
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 8 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í ±³¼ö ¹× °³¿øÀÇ: 80,000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ: 40,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-16 Rm.102 08:00~08:12 How to Assess the Prognosis of TR  Jun-Bean Park(Seoul National Univ. Korea) 
±³À°½Ã°£ 04-16 Rm.102 08:12~08:24 Imaging of the TV, Echocardiography and More  Jin Sun Park(Ajou Univ. Korea) 
±³À°½Ã°£ 04-16 Rm.102 08:24~08:36 Overview of Percutaneous TV Devices  Judy Hung(Massachusetts General Hospital USA) 
Åä·Ð 04-16 Rm.102 08:36~08:45 Discussion  () 
È޽Ġ04-16  08:45~08:55   () 
±³À°½Ã°£ 04-16 Rm.105 08:55~09:10 Overview of Non-Statin Therapies  Laurence Sperling(Emory Univ.USA) 
±³À°½Ã°£ 04-16 Rm.105 09:10~09:15 Case: Fibrates  Jae Bin Seo(Seoul National Univ. Korea) 
Åä·Ð 04-16 Rm.105 09:15~09:20 Discussion  () 
±³À°½Ã°£ 04-16 Rm.105 09:20~09:25 Case: Fish oil, Icosapent Ethyl  Hyun-Jin Kim(Hanyang Univ. Korea) 
Åä·Ð 04-16 Rm.105 09:25~09:30 Discussion  () 
±³À°½Ã°£ 04-16 Rm.105 09:30~09:35 Case: PCSK9 Inhibitors  Youngwoo Jang(Gachon Univ. Korea) 
Åä·Ð 04-16 Rm.105 09:35~09:40 Discussion  () 
È޽Ġ04-16  09:40~09:50   () 
±³À°½Ã°£ 04-16 Rm.205 09:50~10:05 Obesity and Hypertension: Pathophysiologic Link  ÀÌ»ó¿­(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.205 10:05~10:20 Management of Obesity: Beyond Life Style Modifications  ±èº¸¿¬(¼øõÇâÀÇ´ë) 
Åä·Ð 04-16 Rm.205 10:20~10:35 Discussion  () 
È޽Ġ04-16  10:35~10:45   () 
±³À°½Ã°£ 04-16 Rm.205 10:45~10:57 Endurance Exercise: Mostly Good but a Few Concerns  ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.205 10:57~11:09 High‐Intensity Interval Training for Patients with Cardiovascular Disease—Is It Safe?  Á¦¼¼¿µ(¼­¿ï½Ã¸³´ë) 
±³À°½Ã°£ 04-16 Rm.205 11:09~11:14 Endurance exercise (Rebuttal)  ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.205 11:14~11:19 High‐Intensity Interval Training (Rebuttal)  Á¦¼¼¿µ(¼­¿ï½Ã¸³´ë) 
Åä·Ð 04-16 Rm.205 11:19~11:30 Discussion  () 
È޽Ġ04-16  11:30~11:40   () 
±³À°½Ã°£ 04-16 Rm.102 11:40~11:55 Guideline-based Strategy in Lipid Optimization After ACS: When to Check?  ±è¹Îö(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.102 11:55~12:10 Clinical Differentiation of Evolocumab in LDL-C Management  ÀÌ¿øÀç(¼­¿ïÀÇ´ë) 
Åä·Ð 04-16 Rm.102 12:10~12:20 Discussion  () 
È޽Ġ04-16  12:20~12:30   () 
±³À°½Ã°£ 04-16 Rm.300C 12:30~13:15 Interventional Therapy: What¡¯s Next  Roxana Mehran(USA) 
È޽Ġ04-16  13:15~13:20   () 
±³À°½Ã°£ 04-16 Rm.203 13:20~13:40 Monoclonal Antibody and Cardiotoxicty for Cardiologists  º¯ÀÚ¹Î(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.203 13:40~14:00 CAR-T and Potential Cardiotoxicity for Cardiologists  ¹Ú¼º¼ö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.203 14:00~14:20 Immune Check Point Inhibitor and Cardiotoxicity for Cardiologists  ¹Ú¼¼ÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.203 14:20~14:40 Immnunotherapy Related Cardiotoxicity: Cardiologist  ±èÀº°æ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 04-16 Rm.203 14:40~14:50 Discussion  () 
È޽Ġ04-16  14:50~15:00   () 
±³À°½Ã°£ 04-16 Rm.105 15:00~15:10 Differential maneuvers for SVT  ÁøÀº¼±(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.105 15:10~15:20 How to ablate slow pathway without complications  ±èµ¿Çõ(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.105 15:20~15:30 How to ablate difficult accessory pathways  ±èÁø¼®(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.105 15:30~15:40 How to map complex atrial tachycardia  ÀÓÈ«ÀÇ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.105 15:40~15:50 How to map and ablate fascicular ventricular tachycardia  ¹ÚÁø±Ô(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.105 15:50~16:00 How to map and ablate RVOT PVC/VT  ±èÁØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.105 16:00~16:10 How to map and ablate LVOT PVC/VT  ¹Ú°æ¹Î(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.105 16:10~16:20 How to reduce radiation exposure in EP lab  ±èÁø¹è(°æÈñÀÇ´ë) 
Åä·Ð 04-16 Rm.105 16:20~16:30 Discussion  () 
È޽Ġ04-16  16:30~16:40   () 
±³À°½Ã°£ 04-16 Rm.103 16:40~16:52 Pro: CRT for HFrEF with Afib  ±èÀÎö(°è¸íÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.103 16:52~17:04 Con: CRT for HFrEF with Afib  ¹Ú½ÂÁ¤(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.103 17:04~17:09 Pro Rebuttal  ±èÀÎö(°è¸íÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.103 17:09~17:14 Con Rebuttal  ¹Ú½ÂÁ¤(¼º±Õ°üÀÇ´ë) 
Åä·Ð 04-16 Rm.103 17:14~17:25 Discussion  () 
±³À°½Ã°£ 04-16 Rm.103 17:25~17:37 Pro: Stem cell therapy for HF  °­ÁöÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.103 17:37~17:49 Con: Stem cell therapy for HF  Á¶À翵(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.103 17:49~17:54 Pro Rebuttal  °­ÁöÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-16 Rm.103 17:54~17:59 Con Rebuttal  Á¶À翵(Àü³²ÀÇ´ë) 
Åä·Ð 04-16 Rm.103 17:59~18:10 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia (¿Â,¿ÀÇÁ¶óÀÎ)(2ÀÏÂ÷) : 2022-04-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѵÎÅëÇÐȸ 2022³âµµ 4¿ù Mini-Symposium : 2022-04-16
´ÙÀ½±Û ´ëÇѼÒÈ­±âÇÐȸ (¿Â¶óÀÎ) SIDDS 2022 In Conjunction with the Annual Meeting of the KSG (1ÀÏÂ÷) : 2022-04-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21060 ¿ï»ê ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ¿ï»êÁöȸ ¿¬¼ö±³À°(¿ù°æÅë, µ¥³ë¼ö¹ä Áß´Ü ÈÄ ¹Ýµ¿°ñÀýÀÇ ¿¹¹æ) : 2024-07-04 0 7 2024-06-18
21059 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(3ÀÏÂ÷) : 2024-07-03 0 1 2024-06-18
21058 °æ±â 2024³â ÆòÅýÃÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-02 0 12 2024-06-18
21057 ¼­¿ï ¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(2ÀÏÂ÷) : 2024-07-02 0 4 2024-06-18
21056 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 3 2024-06-18
21055 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(1ÀÏÂ÷) : 2024-07-01 0 4 2024-06-18
21054 ÃæºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Understanding Current Community Mental Health and Emotional Disorders in ASD : 2024-07-01 0 6 2024-06-18
21053 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 13 2024-06-18
21052 °æ±â ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦2ȸ CHAMS °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 12 2024-06-18
21051 ¼­¿ï 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ¼­¿ïÁöȸ Çϰ迬¼ö°­Á : 2024-06-30 0 10 2024-06-18
21050 ºÎ»ê 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2024-06-30 0 14 2024-06-18
21049 ¼­¿ï Á¦26Â÷ ´ëÇѾƵ¿º´¿øÇùȸ Ãá°èÇмú´ëȸ : 2024-06-30 0 9 2024-06-18
21048 Ãæ³² 2024 ÀÌ°úÇÐ ¿¬±¸¼¼¹Ì³ª : 2024-06-29 0 5 2024-06-18
21047 ¼­¿ï ´ëÇѽÉÀåÈ£ÈíÀçÈ°ÀÇÇÐȸ Á¦14ȸ Çмú´ëȸ : 2024-06-29 0 9 2024-06-18
21046 ÀÎõ Á¦13Â÷ ÀÎõ½Ã³»°úÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-29 0 7 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷